Proposed Purdue Settlement Bears Positive Effects on I-75 Corridor Opioid Lawsuit

National agreement would settle complaints brought against Purdue by cities/counties, but leaves other defendants to be pursued in court

JACKSBORO, Tenn. — A proposed multi-billion dollar settlement and bankruptcy filing by Purdue Pharma in the national opioid multi-district litigation (MDL) is bearing multiple effects on what is known as the I-75 Corridor opioid lawsuit — including the settlement of complaints brought against the pharmaceutical giant by local cities and counties.

Other manufacturer defendants and distributors remain to be pursued, attorneys say.

The lawsuit was jointly filed on Sept. 29, 2017, in Campbell County Circuit Court in Jacksboro by the district attorneys general of Tennessee’s Sixth, Seventh, Eighth, Ninth and Tenth Judicial Districts, and later amended to also include the Fourth Judicial District. The complaint lists prescription opioid manufacturer Purdue Pharma, L.P. and its related companies, along with Mallinckrodt LLC, Endo Health Solutions, Inc. and its wholly owned subsidiary, Endo Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and alleged local distributors.

“While the agreement — if approved by the bankruptcy court — settles claims made by my office, and on behalf of cities and counties against Purdue, it does not satisfy our complaints against the remaining defendants,” says Jared Effler, district attorney general for Tennessee’s Eighth Judicial District. “More than one pharmaceutical company helped create this crisis. Mallinckrodt, Endo and Teva played significant roles in the overprescription and diversion of opioids in our region, and Purdue’s actions will not alter our focus on holding them accountable, whether in circuit court or bankruptcy proceedings.”

The I-75 Corridor opioid lawsuit is one of three filed in Tennessee by district attorneys general against pharmaceutical manufacturers and other defendants who have contributed to the state’s opioid crisis. In all, 14 district attorneys general representing 47 counties — nearly half the entire state — have joined forces to challenge pharmaceutical manufacturers and distributors for their roles in the opioid epidemic.

That show of solidarity has been instrumental in convincing the industry to face up to its actions, says Gerard Stranch, managing partner of Nashville-based Branstetter, Stranch & Jennings, PLLC (BS&J).

“The district attorneys general who have spoken out on behalf of their cities and communities — many of which are rural areas — should be credited for their tenacity in standing up to Big Pharma,” Stranch says. “They are the ones whose offices expend thousands of hours and millions of dollars prosecuting opioid-related crimes, and they were the first to challenge the manufacturers and distributors in court for their actions. It is their right to hold these companies accountable and also to ensure that financial resources are returned to the communities that have been ravaged by years of overprescription and diversion.”

The I-75 Corridor suit will go to trial in the near future.

“In the two years since we filed this claim, we’ve gathered a massive amount of data on the harmful practices the defendants employed in their pursuit of profit,” Stranch says. “We look forward to sharing this information with the court.”

For additional facts, resources and documentation surrounding this issue, visit


BS&J Managing Partner Appointed as Counsel to Negotiation Class for National Opioid Litigation

NASHVILLE, TENN. — Nashville-based Branstetter, Stranch & Jennings (BS&J), PLLC announces the appointment of managing partner Gerard Stranch as counsel for the negotiation class in the pending multi-district national prescription opioid litigation (MDL 2804) in Cleveland, Ohio.

More than 1,500 cases involving U.S. states, counties, cities and other entities have been consolidated into the MDL. The 49 plaintiffs allege that “the manufacturers of prescription opioids grossly misrepresented the risks of long-term use of those drugs for persons with chronic pain, and distributors failed to properly monitor suspicious orders of those prescription drugs ― all of which contributed to the current opioid epidemic.” The defendants include major pharmaceutical manufacturers Purdue Pharma and Mallinckrodt PLC, distributors McKesson Corporation and Cardinal Health, and major retailers, such as CVS RX Services, Inc.

“I am honored to be appointed to the negotiation class for this complex and pivotal litigation,” Stranch says. “The class provides a tool for the plaintiffs to engage more effectively in settlement discussions, take coordinated action in a comprehensive settlement process, and allocate settlement funds among the entire class at both the state and the city/county levels.

“Throughout this process, it is important to note that the opioid epidemic has impacted rural communities at a much higher rate than urban centers,” Stranch says. “Smaller towns and counties where resources have never been plentiful to begin with are now experiencing disproportionate amounts of suffering. In order to be fair, we should keep in mind that the distribution of settlement funds should accurately reflect the amount of damage inflicted by this crisis.”

Among the six appointees to the proposed class, Stranch is one of three affiliated with a private law firm. The case is currently scheduled to be heard by U.S. District Judge Dan Aaron Polster in October.

For more information about MDL 2840, visit


About Branstetter, Stranch & Jennings, PLLC (  

For more than 65 years, Branstetter, Stranch & Jennings, PLLC has been known for the quality of its advocacy and the integrity of its attorneys. The firm enjoys a national reputation of prominence in the complex litigation arena for its work in class actions, shareholder derivative claims, securities, ERISA, labor and employment, and other complex cases, both at the trial and appellate levels.

Branstetter, Stranch & Jennings, PLLC is dedicated to providing a full range of legal services to its diverse clientele. In addition to providing quality legal services, the firm is proud of the professional and civic leadership its members have provided, both locally and nationally. The firm’s former managing partner, Jane Branstetter Stranch, was nominated by President Obama to the United States Court of Appeals for the Sixth Circuit, and now serves as a judge on that court following her confirmation by the U.S. Senate. Branstetter, Stranch & Jennings, PLLC is listed in the Bar Register of Preeminent Lawyers, and was named among “Best Law Firms” by U.S. News & World Report for 2019, receiving the highest possible Nashville ranking as a Tier 1 in two practice areas.